Animal models and therapeutic molecular targets of cancer: utility and limitations
Authors:
Top Cited Papers
Open Access
- 1 October 2014
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 8, 1911-21
Abstract
Cancer is the term used to describe over 100 diseases that share several common hallmarks. Despite prevention, early detection, and novel therapies, cancer is still the second leading cause of death in the USA. Successful bench-to-bedside translation of basic scientific findings about cancer into therapeutic interventions for patients depends on the selection of appropriate animal experimental models. Cancer research uses animal and human cancer cell lines in vitro to study biochemical pathways in these cancer cells. In this review, we summarize the important animal models of cancer with focus on their advantages and limitations. Mouse cancer models are well known, and are frequently used for cancer research. Rodent models have revolutionized our ability to study gene and protein functions in vivo and to better understand their molecular pathways and mechanisms. Xenograft and chemically or genetically induced mouse cancers are the most commonly used rodent cancer models. Companion animals with spontaneous neoplasms are still an underexploited tool for making rapid advances in human and veterinary cancer therapies by testing new drugs and delivery systems that have shown promise in vitro and in vivo in mouse models. Companion animals have a relatively high incidence of cancers, with biological behavior, response to therapy, and response to cytotoxic agents similar to those in humans. Shorter overall lifespan and more rapid disease progression are factors contributing to the advantages of a companion animal model. In addition, the current focus is on discovering molecular targets for new therapeutic drugs to improve survival and quality of life in cancer patients.Keywords
This publication has 136 references indexed in Scilit:
- Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathwaysMolecular Cancer Therapeutics, 2008
- Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionshipChromosome Research, 2008
- Tissue-specific and reversible RNA interference in transgenic miceNature Genetics, 2007
- Combined Vascular Endothelial Growth Factor–Targeted Therapy and Radiotherapy for Rectal Cancer: Theory and Clinical PracticeSeminars in Oncology, 2006
- Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expressionNuclear Medicine and Biology, 2006
- Spontaneous and genetically engineered animal modelsEuropean Journal of Cancer, 2004
- Orthotopic models of cancer for preclinical drug evaluationEuropean Journal of Cancer, 2004
- Effects of an Rb mutation in the mouseNature, 1992
- Fifteen cases of prostatic carcinoma in the dogVeterinary Record, 1981